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RECOMBINANT APROTININ 
IN CORONARY ARTERY 
BYPASS GRAFT 
OPERATIONS 
Objective: To evaluate the role of recombinant bovine aprotinin in reducing 
blood loss in coronary artery bypass graft surgery. Design: An open-label, 
randomized, controlled study evaluating two dosage levels of recombinant 
aprotinin. Setting: Two acute care hospitals (Northwestern Memorial 
Hospital, Chicago, Ill., and the Scott & White Memorial Hospital, Temple, 
Texas). Patients: Patients undergoing primary and reoperation coronary 
artery bypass grafting were assigned to groups by means of a computer- 
generated table of random numbers. Treated (n = 48) and control (n = 36) 
patients did not differ significantly in age, sex, weight, number of grafts, or 
preoperative hemoglobin level. Interventions: Recombinant aprotinin was 
given at two dosages. Dosage level 1 consisted of a bolus of 2 mg/kg 
intravenously immediately after the induction of anesthesia, 1 mg/kg added 
to each liter of the oxygenator prime, and 0.5 mg • kg -1 • hr - l  infused 
continuously during operation. At dosage level 2, doses were doubled. 
Intraoperative monitoring of anti-factor Xa activity was performed, and 
additional doses of heparin were given on the basis of anti-factor Xa 
results. Main outcome measures: Preoperative and postoperative h moglobin 
levels, amounts of autotransfusion device and chest tube drainage blood, 
and transfusions of allogeneic red blood cells. Adverse clinical events 
(alterations in renal function, graft thrombosis, myocardial infarction, and 
death) were recorded. Results: Additional heparin was given to 48% patients 
in the aprotinin group and to 44% of control patients. Overall red blood cell 
loss (in milliliters, mean _ standard eviation [SD]) was decreased with 
aprotinin at dosage level 1 for reoperations (1040 - 162 vs 1544 -+ 198,p < 
0.01), and at dosage level 2 for all operations (primary operations, 886 - 
362 vs 1333 - 618,p = 0.02; reoperations, 1191 - 560 vs 1815 ± l l16,p = 
0.2). Fewer patients in the aprotinin than in the control group had 
transfusions of donated blood (6/48 vs 12/36, p = 0.02) or reinfusion of 
chest tube drainage blood (12/48 vs 20/36, p < 0.01). Among patients 
receiving dosage level 1, there were no myocardial infarctions or deaths. At 
dosage level 2, one patient had profound bradycardia nd died on day 12 
and two patients had late graft closures. Two control patients had 
hypotension after bypass necessitating intraaortic balloon pumps, and one 
of these patients died. Postoperative increases in blood urea nitrogen and 
creatinine levels were small in both aprotinin and control groups. No hyper- 
sensitivity or other allergic reactions occurred. Conclusion: We conclude that, 
at the dosages given, recombinant bovine aprotinin decreases surgical blood 
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loss and transfusion requirements in patients undergoing coronary artery bypass 
grafting, but its use requires appropriate monitoring of heparin use during bypass. Whether 
higher dosages ofaprotinin increase the risk of graft thrombosis must be further assessed 
with a larger patient sample. (J THORAC CARDIOVASC SURG 1995;110:963-70) 
I mproved surgical techniques and equipment have resulted in major reductions in blood loss during 
coronary artery bypass grafting (CABG) operations. 
In December 1993, the U.S. Food and Drug Admin- 
istration approved aprotinin, a polyvalent protein- 
ase inhibitor derived from bovine tissue. This is a 
polypeptide of 58 aminoacids that has a molecular 
weight of about 6500 daltons. In several trials, 
aprotinin was shown to significantly limit blood loss 
and the need for blood replacement. 1-3 Q-wave 
myocardial infarction, acute vein graft thrombosis, 
disseminated intravascular coagulation, renal dys- 
function, and severe allergic reactions have been 
reported in conjunction with aprotinin treatment, 3'4 
and these reports raise questions about the safety of 
the drug. 
To avoid bovine tissue as the source of produc- 
tion, Novo Nordisk A/S (Copenhagen, Denmark) 
developed processes to produce recombinant 
bovine aprotinin (r-Apr) by fermentation using 
S. cerevisiae as the production organism. The 
recombinant protein appears to be identical with 
native aprotinin and is prepared with a purity of 
about 99%, as determined by high-pressure liquid 
chromatography. 5 It is supplied in vials of 50 ml 
containing 1.4 mg/ml of r-Apr with an activity of 
10,000 kallikrein inhibitory units (KIU) per milli- 
liter. Studies in rats, cats, and pigs showed no 
differences between r-Apr and native aprotinin 
with respect o either pharmacokinetics or phar- 
macodynamics. 6 
We have evaluated the safety and effectiveness of
r-Apr in patients undergoing either primary CABG 
or reoperations. Two dosage levels of the drug were 
studied; one was equivalent to the currently recom- 
mended osage of native aprotinin and one was half 
this dosage. The lower dosage was evaluated at 
Northwestern Memorial Hospital (Chicago, Ill.), 
and the other dosage was evaluated at both North- 
western and the Scott & White Clinic (Temple, 
Texas). The effect of r-Apr on blood loss, transfu- 
sion requirements, and the results of safety moni- 
toring are presented. The data indicate that r-Apr is 
a valuable agent for safely decreasing bleeding in 
patients undergoing CABG. 
Methods 
Subjects. Consecutive patients requiring primary 
CABG or reoperations were recruited for this study. 
Patients were excluded if they had had a myocardial 
infarction within the previous 7 days, had an ejection 
fraction of less than 30%, had intractable congestive heart 
failure, were older than 79 years, or had received aspirin 
within 72 hours of operation. In addition, patients were 
ineligible if serum creatinine level exceeded 2 mg/dl, 
hematocrit was less than 30%, platelet count was less than 
100,000 cells//zl, or the prothrombin time was above the 
normal reference range. 
Study design. This was an open-label, randomized clin- 
ical trial conducted in two phases. In phase 1, patients 
assigned to the r-Apr group received 2 mg/kg (14,300 
KIU/kg) as an intravenous bolus given in 20 minutes after 
the induction of anesthesia, n intravenous infusion of 
0.5 mg • kg  -1  • hr -1 (3570 KIU • kg -~ • hr -1) until the 
patient left the operating room, and 1 mg/kg (7143 KIU) 
added to each liter of lactated Ringer's solution for 
priming of the membrane oxygenator. In phase 2, each 
dose was doubled. Studies of dosage level 1 were per- 
formed in Chicago (42 patients), and studies of dosage 
level 2 were conducted both in Chicago (26 patients) and 
in Temple, Texas (16 patients). Patients were stratified 
according to center, surgeon (four in Chicago and two in 
Temple), and type of operation. Within each stratum, 
patients were assigned to groups by means of a computer- 
generated table of random numbers in permuted blocks of 
five for primary operations and two for reoperations. The 
study was approved by both institutions' Human Subjects 
Review Boards. 
The sample size calculation was based on estimates of 
blood loss previously determined in patients undergo- 
ing CABG at Northwestern Memorial Hospital. For 
those undergoing primary CABG, the calculations in- 
dicated that it would be possible to show a difference 
greater than or equal to 1.2 SDs with a power of 90% 
and a significance level of 5% if 30 patients were 
evaluated at each dosage level. For those undergoing 
reoperations, 12 patients would be needed at each 
dosage level to show a difference 1.7 SDs with a power 
of 90% and a significance level of 5%. For primary 
operations, random assignment in a 3:2 ratio for the 
r-Apr versus control groups was calculated to result in 
a power loss of less than 5%. For reoperations, the ratio 
of r-Apr to control groups was 1:1. The random assign- 
ment was done for each participating surgeon. 
Intraoperative monitoring of heparin. All patients 
received heparin at 300 U/kg immediately before cannu- 
lation of the aorta. Because aprotinin prolongs the hepa- 
rin dotting time, as measured by the Celite-activated 
clotting time (ACT) test (Manville Service Corp., Denver, 
Colo.), 7 anticoagulation was monitored uring cardiopul- 
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monary bypass by means of a modified amidolytic anti- 
factor Xa assay, s A microcentrifuge (StatSpin Technolo- 
gies, Norwood, Mass.) and enzyme-linked immunosorbent 
assay plate reader were mounted on a mobile cart, which 
was stationed adjacent o the operating theater. Blood 
samples were obtained at 30-minute intervals until the end 
of bypass or as clinically indicated. The blood was col- 
lected in tubes containing 3.8% sodium citrate and was 
immediately centrifuged for 2 minutes. The anti-factor 
Xa activity was measured as follows: plasma was diluted 
1:30 in Tris(hydroxymethyl)aminomethane (Tris) buffer, 
pH 8.4; normal pooled plasma, controls, and standards 
were similarly diluted. Diluted samples were then placed 
in the wells of microtiter plates, incubated with antithrom- 
bin III (KabiVitrum AB, Stockholm, Sweden), and then 
factor Xa (Kabi) was added, followed 1 minute later by 
S-2222 (Kabi). The reaction was stopped at 5 minutes by 
the addition of COA Stopbuffer (Kabi), pH 3.0. The 
absorbance ofthe mixture at 405 nm was recorded with the 
enzyme-linked immunosorbent assay plate reader, with 620 
nm used as reference. The anti-factor Xa levels of the 
patient samples were determined according to a standard 
curve constructed from readings of the standards at various 
heparin concentrations. All samples were run in duplicate. 
Additional heparin was given whenever the anti-factor 
Xa levels fell below 3.0 U/ml according to the following 
nomogram: anti-factor Xa 2.5 to 2.9 U/ml, 50 U/kg 
heparin; anti-factor Xa 2 to 2.4 U/ml, 100 U/kg heparin; 
anti-factor Xa 1.5 to 1.9 U/ml, 200 U/kg heparin; and 
anti-factor Xa less than 1.5 U/ml, 300 U/kg heparin. The 
effect of heparin was reversed by giving 1 mg protamine 
sulfate for every 100 U of heparin given at the time of 
cannulation. 
The Cell-Saver autotransfusion device (Haemonetics 
Corp., Braintree, Mass.) was used in every operation, and 
all blood that could be suctioned from the operative field 
was processed and returned to the patient. This included 
blood remaining in the pump circuit. In addition, blood 
from the chest ube drains was also reinfused if the total 
volume exceeded 150 ml. Units of allogeneic (donor) 
blood were transfused according to the following criteria: 
during cardiopulmonary b pass if the hemoglobin level 
was less than 5 gm/dl; after bypass if all autransfusion 
device blood had been infused and the hemoglobin level 
was still less than 7 gm/dl; and on the first and subsequent 
postoperative days if the hemoglobin level was less than 7 
gm/dl. 
Laboratory investigations. All patients underwent 
complete blood cell counts and tests of renal function 
before operation. Blood was collected at 30-minute inter- 
vals during bypass; at 1, 4, and 24 hours after operation; 
and at postoperative day 5. In these samples hemoglobin, 
blood urea nitrogen (BUN), and creatinine levels were 
measured. Samples were taken at 1 and 6 months for 
determination of antibodies against potential yeast con- 
taminants and r-Apr. 
To assess perioperative bleeding, the volume and he- 
matocrit of the chest tube drainage were measured and 
erythrocytes lost were calculated by multiplying the drain- 
age volume (ml) by the hematocrit. The amounts and 
types of all transfused fluids were also recorded. Loss of 
erythrocytes was calculated from the following expression: 
Table I. Patients excluded from the study 
Patients 
Criterion excluded 
Aspirin within past 72 hr 31 
Age >79 yr 16 
Ejection fraction <30% 15 
Myocardial infarction within the past week 7 
Creatinine >2 mg/dl 4 
Other sources of blood loss 4 
Prothrombin time >15 sec 3 
Platelet count <100,000 cells//~l 2 
Hematocrit <30% 1 
Operation cancelled 12 
Patient refusal 21 
TOTAL 116 
Erythrocyte loss = BV × AHct 
where BV is blood loss weight in kg × 60 ml/kg and AHct is 
preoperative hematocrit minus day 5 hematocrit. Day 5 was 
selected because by that time patients were in stable condi- 
tion and were no longer eceiving transfusions. To determine 
overall erythrocyte loss, the calculated erythrocyte loss and 
the erythrocyte content (hematocrit times volume) of all 
transfused blood were summed. This included autotrans- 
fused blood (hematocrit 50%) and allogeneic packed eryth- 
rocytes (hematocrit 80%). Nonstudy personnel measured 
the amounts of chest ube drainage, autotransfusion device 
blood, and allogeneic erythrocytes infused. 
Follow-up evaluation. All patients were seen at 1 and 6 
months after discharge, and information was recorded 
regarding chest pain, angina of new onset, myocardial 
infarction, or other thrombotic events. 
Statistical methods. All data were expressed as the mean 
+-- SD. Comparisons between groups were made with a t test 
for independent samples or the nonparametric Wilcoxon 
rank-sum test, SAS version 6.08 procedures TrEST and 
NPARlWAY, respectively (SAS Institute, Inc., Cary, N.C.). 
Nonparametric tests were used if the data did not have a 
normal distribution and equal variance, as determined by a 
standard F test for equal variances and the Shapiro-WiUks 
test for normality. When categoric measures were compared 
between patient groups, Pearson's X2 test was used. A p 
value of less than 0.05 was considered significant. 
Results 
Patients. Two hundred consecutive patients were 
screened, and 116 were excluded for the reasons 
shown in Table I. Table II shows the baseline charac- 
teristics of the study participants. Most patients were 
male and in their early sixties. There were no signifi- 
cant differences between study groups with respect o 
weight or number of grafts inserted. As planned, two 
thirds of the patients undergoing primary opera- 
tions received r-Apr at each dosage level; half of 
the patients undergoing reoperations received r- 
Apr at each dosage level. All of the patients 
undergoing reoperations had initially undergone 
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Table II. Baseline characteristics of study subjects* 
Al l  subjects Dosage level 1 Dosage level 2 
r-Aprotinin Control r-Aprotinin Control r-Aprotinin Control 
n 48 36 24 18 24 18 
Age (yr) 62 ± 9 63 ± 8 64 _+ 8 63 ± 8 60 ± 9 64 ___ 8 
Sex (M/F) 39/9 31/5 20/4 16/2 19/5 15/3 
Weight (kg) 87 ± 15 82 ± 12 83 ± 11 82 _+ 12 90 --+- 18 82 ___ 12 
No. of grafts 3.6 ± 1.2 3.5 _+ 0.9 3.3 --_ 1.2 3.4 ± 1.1 3.8 ± 1.0 3.56 ± 0.6 
Primary operations 36 24 18 12 18 12 
Reoperations 12 12 6 6 6 6 
*p > 0.1 for all comparisons. 
Table III. Estimated blood loss (milliliters of erythrocytes; mean +__ SD) at the two dosage levels of 
r-Apr studied 
Dosage level I Dosage level 2 
r-Apr Control p r-Apr Control p 
Primary operations (n = 60) n = 18 n = 12 n = 18 n = 12 
Hemoglobin (gm/dl) 
Baseline 13.8 ___ 1.9 13.1 __+ 1.6 NS 13.9 ± 1.4 13.5 ± 1.4 NS 
Day 5 11.0 ± 2.4 10.4 ± 1.4 NS 10.7 -L-_ 2.2 9.8 +- 1.2 NS 
Calculated erythrocyte loss (ml)* 419 _+ 335 399 ___ 239 NS 517 ± 393 532 ± 258 (11) NS 
Autotransfusion device erythrocytes (ml) 418 ± 148 441 _+ 117 NS 337 ± 245 619 ± 380 0.02 
Overall erythrocyte loss (ml)t 916 ± 363 (17) 905 ± 206 (11) NS 886 _+ 362 1333 -+ 618 (9) 0.02 
Chest tube drainage rythrocytes (ml) 48 ± 35 (15) 113 ± 55 (11) <0.001 60 _ 34 (14) 152 ± 57 (8) <0.001 
Reoperations (n = 24) n = 6 n = 6 n = 6 n = 6 
Hemoglobin (gm/dl) 
Baseline 13.1 ± 1.0 13.5 ± 1.3 NS 14.3 ± 1.5 14.0 ± 2.2 NS 
Day 5 10.1 ± 1.9 9.6 ± 1.5 NS 10.4 ± 1.9 9.5 ± 1.3 NS 
Calculated erythrocyte loss (ml)* 456 ± 259 536 ± 287 (4) NS 633 ± 478 717 --- 274 (5) NS 
Autotransfusion device erythrocytes (ml) 563 -+ 136 539 _+ 176 NS 459 ± 386 656 ± 467 NS 
Overall erythrocyte loss (ml)t 1040 ± 162 1544 ± 198 (4) 0.01 1191 ± 560 1815 ± 1116 (5) NS 
Chest tube drainage rythrocytes (ml) 38 +- 16 (5) 108 4- 19 (4) <0.001 33 ± 24 (4) 214 ± 151 (4) 0.02 
Numbers in parentheses refer to number of patients tudied. NS. Not significant. 
*Calculated erythrocyte loss = blood volume X (hematocrit on day 1 - hematocrit on day 5) 
tOverall erythrocyte loss = calculated erythrocyte loss + autotransfusion device erythrocytes + predonated erythrocytes 
CABG and required reoperation for closed grafts, 
progression of atherosclerotic disease in the native 
coronary arteries, or both of these conditions. The 
maximum degree of hypothermia used was 29 ° C. 
Bypass times (in hours, mean ___ SD) were as 
follows: dosage level 1 for primary operations, con- 
trol 2.58 _ 0.9, r-Apr 2.25 ___ 0.52; dosage level 1 for 
reoperations, control 2.79 +__ 0.72, r-Apr 2.38 ___ 0.37; 
dosage level 2 for primary operations, control 2.14 
+__ 0.49, r-Apr 2.22 +_ 0.64; dosage level 2 for 
reoperations, control 3.02 __+ 0.74, r-Apr 2.94 _+ 0.46 
(p > 0.1 for all comparisons by t test). No patients 
received platelet concentrates, fresh-frozen plasma, 
desmopressin, or antifibrinolytic agents. 
Intraoperative monitoring. We examined the 
ACT and anti-factor Xa values in all patients. The 
mean ACT (_ SD) for those receiving r-Apr was 
721 _+ 179 seconds, compared with 582 __+ 154 
seconds for control patients (p = 0.001). The anti- 
factor Xa values, however, were 3.6 ___ 0.7 U/ml 
versus 3.5 _+ 0.7 U/ml (p = ns). Additional heparin 
was given on the basis of anti-factor Xa values 
rather than ACT results. Twenty-three (48%) of the 
48 patients treated with r-Apr and 16 (44%) of the 
36 control patients (p = ns) were given additional 
heparin. Heparin dosing in the r-Apr groups was 
similar to that in the control group because the anti- 
factor Xa assay was used to monitor heparin levels. 
Blood loss. Table III shows the results of moni- 
toring of blood loss during the perioperative p riod. 
Baseline hemoglobin values were similar in all pa- 
tient groups. Hemoglobin was measured repeatedly 
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after operation; the values on day 5 are representa- 
tive and do not reveal any significant differences 
between r-Apt treated or control patients, either at 
dosage level 1 or 2, or for primary or reoperations. 
This is because patients were transfused with auto- 
transfusion device blood, chest tube blood, or do- 
nated blood as described in the Methods section. 
However, the amount of autotransfusion device 
blood (in milliliters of erythrocytes, mean +__ SD) 
given to patients in the r-Apr groups was generally 
less than that given to control patients: primary 
operations at dosage level 1,418 +__ 148 versus 441 _ 
117 (p = 0.7); primary operations at dosage level 2, 
337 _ 245 versus 619 _+ 380 (p = 0.02, Wilcoxon 
rank-sum test); reoperations atdosage level 1, 563 --+ 
136 versus 539 _ 176 (p = 0.8); reoperations at dosage 
level 2, 459 _+ 386 versus 656 _ 467 (p = 0.8, Wilcoxon 
rank-sum test). Furthermore, the proportion of pa- 
tients in the r-Apr groups needing allogeneic blood or 
chest ube drainage transfusion was significantly ower 
than in the control group (Table IV). 
We calculated the total erythrocytes lost by each 
patient on the basis of change in hematocrit, amount 
of autotransfusion device erythrocytes infused, and 
amounts of chest ube drainage and donor erythro- 
cytes given (Fig. 1 and Table III). Overall erythro- 
cyte losses (in milliliters, mean _ SD) were as 
follows: for primary operations, dosage level 1 was 
916 _ 363 for r-Apr versus 905 _ 206 for control 
(p = 0.9) and dosage level 2 was 886 ± 362 versus 
1333 _ 618 (p = 0.02); for reoperations, dosage 
level 1 was 1040 ± 162 versus 1544 ___ 198 (p = 0.01) 
and dosage level 2 was 1191 __+ 560 versus 1815 _+ 
1116 (p = 0.2, Wilcoxon rank-sum test). These 
differences in blood loss between r-Apr and control 
groups were mirrored by the measurements of total 
erythrocytes lost in the chest tube drainage fluid. 
For primary operations at dosage level 1, erythro- 
cytes lost were 47 -+ 35 ml versus 113 ± 55 ml (p < 
0.001), and for dosage level 2, they were 60 _+ 34 ml 
versus 152 ± 57 ml (p < 0.001). For reoperations at
dosage level 1, erythrocyte losses were 38 _+ 16 ml 
versus 108 ± 19 ml (p < 0.001), and for dosage level 
2, they were 33 +__ 24 versus 214 ± 151 (t9 = 0.02). 
We also compared blood losses between the two 
r-Apr dosage levels for both primary operations and 
reoperations. There were no significant differences 
in day 5 hemoglobin concentrations, milliliters of 
autotransfusion device blood infused, hemoglobin 
the drainage fluid, or total blood loss. 
Adverse reactions. At dosage level 1 of r-Apr, 
none of the patients had recurrence of angina, had 
Table IV. Numbers of patients requiring 
transfusions of allogeneic blood or chest ube 
drainage blood (when total volume >150 ml) 
Primary 
operations Reoperations Total 
Allogeneic blood 
Aprotinin 4/36 2/12 6/48 
Control 6/24 6/12 12/36 
p 0.02 
Chest ube blood 
Aprotinin 9/36 3/12 12/48 
Control 15/24 5/12 20/36 
p <0.01 
new myocardial infarction, or died. Two patients in 
the control group, however, had hypotension after 
bypass and required an intraaortic balloon pump; 
one of these patients died. At dosage level 2, there 
were three adverse vents. At the Temple site, one 
patient undergoing primary operation had a late 
graft closure (day 133); one undergoing reoperation 
had a myocardial infarction on day 28. The third 
patient underwent reoperation at the Chicago site; 
profound bradycardia developed after extubation, 
and respiratory failure was followed by death on day 
12. Creatine kinase measurements and electrocar- 
diography did not reveal evidence of myocardial 
injury; postmortem examination was not permitted. 
The changes in BUN and creatinine levels from 
baseline to day 5 values were examined for control 
patients and patients receiving r-Apr (Table V). The 
changes were small for all groups; there was a 
statistically significant but clinically unimportant in- 
crease in BUN and creatinine levels in patients 
undergoing primary operations and receiving dos- 
age level 2 of r-Apr. One patient in the r-Apr group 
who underwent reoperation had an increase in BUN 
to 70 mg/dl, an increase in creatinine level to 2.6 
mg/dl, and a urinary tract infection, which was 
treated. One week later, the BUN and creatinine 
values were normal. No hypersensitivity or other 
allergic reactions were observed. 
Discussion 
The main results of this study are that r-Apr 
decreased blood loss as well as the need for trans- 
fusions in patients undergoing CABG. The conser- 
vation of blood noted in this investigation is compa- 
rable to that previously reported for aprotinin 
derived from bovine lungs. 9 Importantly, efficacy 
was observed at a dosage level of r-Apr that corre- 
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Dose  Level  l 
pr imary  re-  
surgery  operat ions  
Dose  Level  2 
primary re- 
surgery operations 
apr con apr con apr con apr con 
¢¢ ¢¢~ 
p=0.01 p=0.02 
Fig. 1. Cumulative blood losses (milliliters of erythrocytes [RBC]) in patients undergoing primary operations or 
reoperations and receiving dosage level 1 or dosage level 2 of PA W (apr) or no aprotinin (con). Stippled area presents 
calculated milliliters of erythrocytes lost a  derived from blood volume and change in hematocrit from baseline to 
postoperative day 5. Shaded area represents milliliters of autotransfusion device erythrocytes infused, and cross-hatched 
area represents milliliters of allogeneic or chest tube erythrocytes transfused. 
Table V. Changes (baseline minus day 5) in BUN and creatinine levels in all patient groups (mean +_ SD) 
BUN (mg/dl) Creatinine (mg/dl) 
r-Apr Control p r-Apr Control p 
Primary operations 
Dose level 1 -4 .7  ± 6.0 -3 .2  ± 6.0 NS 0.02 ± 0.2 0.00 _+ 0.2 NS 
Dose level 2 -5 .7  ± 10.2 -2 .9  ± 9.8 NS -0.11 ± 0.3 0.08 --- 0.3 0.04 
Reoperations 
Dose level 1 -1 .8  ± 4.8 -6 .3 ± 9.4 NS -0.02 ± 0.2 -0 .17 ± 0.1 NS 
Dose level 2 -13.0 -+ 24.1 -0.6 ± 5.1 NS -0.53 --- 1.7 0.20 --- 0.2 NS 
NS, Not significant (p > 0.1). 
sponded to only half the dosage currently recom- 
mended for bovine lung aprotinin (bolus dose of 280 
mg [2 × 106 KIU], oxygenator p ime of 280 mg [2 × 
106 KIU], and continuous infusion of 70 mg/hr 
[0.5 X 106 K IU] .  Cosgrove and coworkers 3 also 
reported that efficacy was retained if only half the 
dosage of bovine lung aprotinin was given. Others 
have experimented with adding bovine lung aproti- 
nin to the pump prime alone, but efficacy in these 
studies has been inconsistent. 1°-i2 It should be noted 
that the results of others are not directly comparable 
to those in our studies because other studies did not 
use r-Apr and aprotinin dose was not based on body 
weight. The main benefit of the low-dose r-Apr was 
seen in patients undergoing reoperations; even in 
patients undergoing primary operations, however, 
there was a trend toward lessened use of allogeneic 
blood, a significant decrease in units of blood auto- 
transfused, and a decrease in drainage hemoglobin. 
Patients undergoing reoperations and receiving 
standard osage r-Apr also had less blood loss, but 
the values between standard ose and Control did 
not reach statistical significance because of the small 
number of subjects tudied and the wide variations 
in individual blood loss. 
Our blood loss data may be biased by the fact that 
it is extremely difficult to accurately determine in- 
traoperative blood l ss. Blood lost to the surgical 
drapes and sponges cannot be measured or re- 
trieved. In addition, the autotransfusion device 
blood included blood remaining in the cardiopulmo- 
nary bypass circuit at the end of the operation. This 
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volume of blood is variable and depends on patient 
factors not necessarily associated with blood loss. 
This variability may have influenced the overall 
erythrocyte loss calculations. Although the calcu- 
lated blood losses did not differ between r-Apr and 
control groups, this was because patients were trans- 
fused according to a standard protocol. Importantly, 
patients in the r-Apr groups received significantly 
less allogeneic and chest ube drainage rythrocytes. 
Other factors known to affect perioperative blood 
loss, including age, sex, surgeon, total cardiopulmo- 
nary bypass time, and aspirin use, were controlled 
for or did not differ between groups. 
The mechanisms by which aprotinin decreases 
bleeding associated with heart operations are still 
unclear. It has been suggested that aprotinin, by 
virtue of its ability to inhibit serine proteases, may 
prevent platelet activation and the degradation of 
platelet membrane glycoproteins by plasmin as well 
as averting premature lysis of the hemostatic 
clot. 13-16 In a companion study, 17 we measured a
variety of indexes of platelet function and hemo- 
static factor activity in subjects treated with r-Apr 
and in control subjects. The major finding was that 
expression of platelet GMP-140, a protein located 
on the inner membrane of the platelet alpha gran- 
ule, was less increased in treated patients than in 
control patients. This suggests lesser platelet activa- 
tion. Other observations included a decline in the 
expression of platelet surface glycoprotein Ib and an 
increase in the release of/3-thromboglobulin during 
bypass, but these were similar in patients treated 
with r-Apr and control patients. In addition, no 
differences were noted in platelet numbers or 
plasma levels of fibrinogen or fibrinopeptide A. It 
may be that aprotinin acts on the platelet-vessel wall 
interaction because, as shown by Kestin and col- 
leagues, 18 cardiopulmonary bypass results in poor 
platelet reactivity to an in vivo wound but normal 
platelet function in vitro and no intrinsic platelet 
defects. Future studies hould focus on the bleeding 
time and measurements of thromboxane A2 and 
other platelet agonists in the shed blood of patients 
undergoing bypass operations with and without 
aprotinin. 
The principal concern in the use of aprotinin is 
thrombosis; graft occlusion, myocardial infarction, 
disseminated intravascular coagulation, and deaths 
from thrombosis have all been attributed to the 
drug. 3'4 Some of these thrombotic events, however, 
may have been caused by inadequate dosing with 
heparin as a result of interference with the ACT by 
aprotinin. 19 Aprotinin inhibition of coagulation 
serine proteases augments the prolongation of the 
ACT by heparin, making heparin dosage adjust- 
ments based on the ACT unreliable. In our study, 
heparin underdosage was avoided by using a rapid 
anti-factor Xa assay, which was unaffected by apro- 
tinin. This resulted in patients treated with r-Apr 
receiving amounts of heparin comparable to dos- 
ages given to control subjects. Nevertheless, two 
patients receiving the higher dosages of r-Apr had 
graft occlusion (although one occurred 133 days 
after operation), and a third patient died. Even with 
adequate heparinization, there may be a thrombotic 
risk with currently used dosages of aprotinin. 
Whereas angiographically controlled studies of 
aprotinin have not shown a greater incidence of 
graft thrombosis in treated patients than in control 
subjects, 2°there is a clear need for more studies to 
evaluate the safety of aprotinin. 
Allergic reactions, including anaphylaxis, 21have 
been reported in patients treated with bovine lung 
aprotinin (0.6% in the series reported by Royston9); 
no such reactions were observed in this trial at either 
dosage level of r-Apr. In addition, there were no 
important changes in renal function attributable to 
the agent. We conclude that r-Apr effectively dimin- 
ishes surgical bleeding and the need for transfusions 
in patients undergoing CABG, but its use requires 
careful monitoring of intraoperative heparin use. 
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